<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3712">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234649</url>
  </required_header>
  <id_info>
    <org_study_id>RP10-012</org_study_id>
    <nct_id>NCT01234649</nct_id>
  </id_info>
  <brief_title>Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)</brief_title>
  <official_title>Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future&#xD;
      health of the mother. GDM is often the culmination of years of unrecognized and unmodified&#xD;
      diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy.&#xD;
      Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will&#xD;
      develop type 2 diabetes (DM2) at rates much greater than control groups who did not have&#xD;
      glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression&#xD;
      in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to&#xD;
      increase in animal models. This study will examine if the addition of liraglutide to&#xD;
      metformin therapy is more effective than metformin alone in improving insulin sensitivity and&#xD;
      normalizing insulin secretion in at-risk overweight/obese women with prior GDM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes is often the culmination of years of unrecognized and unmodified&#xD;
      diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy.&#xD;
      . Despite the high and increasing rate of type 2 diabetes in Louisiana, the medical community&#xD;
      does not have reliable estimates of the number of woman living in southern Louisiana who&#xD;
      develop diabetes subsequent to GDM. Systematic reviews of older studies conclude that 35-60%&#xD;
      women with gestational diabetes will develop type 2 diabetes at rates much greater than&#xD;
      control groups who did not have glucose intolerance during pregnancy. The higher rates were&#xD;
      in studies of particular ethnic groups in the U.S. Recently, follow-up programs elsewhere&#xD;
      also have identified increasing rates of type 2 diabetes by 5-10 years after GDM: 9-43% type&#xD;
      2 diabetes in Europe and 11-21% in Asia. The frequency of type 2 diabetes is influenced by&#xD;
      BMI, weight gain after pregnancy, family history of diabetes, fasting and postchallenge&#xD;
      glucose levels during and after pregnancy, postpartum insulin resistance and inadequate&#xD;
      β-cell secretion, and the need for pharmacological treatment during pregnancy. However, the&#xD;
      risk factors are unable to predict all cases of subsequent type 2 diabetes: the biggest risk&#xD;
      factor is a GDM pregnancy. Presently, in the literature, there are described new, more&#xD;
      efficient methods of diabetes prevention in groups with a high risk of this disorder, which&#xD;
      involve both, lifestyle modification and pharmacological therapies. Lifestyle intervention&#xD;
      was found to reduce the incidence of type 2 diabetes by 58% and metformin by 31% as compared&#xD;
      with placebo. The use of rosiglitazone in subjects with prediabetes resulted in a 60%&#xD;
      reduction of the diabetes incidence rate. Studies are needed for optimal postpartum and&#xD;
      long-term health of women who have had GDM. Considerable recent evidence suggests that&#xD;
      incretin-based therapies may be useful for the treatment of DM2 because continuous&#xD;
      administration of glucagon-like peptide 1 (GLP-1) produces substantial improvements in&#xD;
      glucose control and ß-cell function in subjects with type 2 diabetes. Infusion of GLP-1&#xD;
      improves first and second-phase insulin secretion suggesting that early GLP-1 therapy may&#xD;
      preserve ß-cell function in subjects with IGT or mild DM2. Whereas native GLP-1 has a very&#xD;
      short half-life, the GLP-1 analogue liraglutide has a prolonged action (t1/2=13 h) suitable&#xD;
      for once-daily injection. Liraglutide may potentially delay disease progression in GDM&#xD;
      considering the ß-cell function improvement in DM2 and ß-cell mass shown to increase in&#xD;
      animal models. This study will examine if the addition of liraglutide to metformin therapy is&#xD;
      more effective than metformin alone in improving metabolic parameters in at-risk&#xD;
      overweight/obese women with prior GDM&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2011</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion-Sensitivity Index (IS-SI)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose (FBG)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Fasting glucose levels in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose During OGTT (MBG)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Insulin Sensitivity Index Derived From OGTT</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic Index (IGI) /HOMA-IR</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Body Weight</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Body weight in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)</measure>
    <time_frame>Change from baseline (time 0) to study end (84 weeks)</time_frame>
    <description>Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (WC)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Hip Ratio (WHR)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist to Height Ratio (WHtR)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (CHOL) Levels</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>CHOL levels in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-C) Levels</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>HDL-C levels in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-C) Levels</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TRG) Levels</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>TRG concentrations in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>SBP in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>DBP in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio</measure>
    <time_frame>84 weeks of treatment</time_frame>
    <description>ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Disorder of Glucose Regulation</condition>
  <arm_group>
    <arm_group_label>Metformin XR plus liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin XR plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR plus placebo</intervention_name>
    <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
    <arm_group_label>Metformin XR plus placebo</arm_group_label>
    <other_name>Metformin XR is generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR plus liraglutide</intervention_name>
    <description>Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
    <arm_group_label>Metformin XR plus liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult female 18 years to 45 years of age who experienced GDM within 52 weeks of index&#xD;
             pregnancy&#xD;
&#xD;
          -  Actual BMI &gt;25 kg/ m2&#xD;
&#xD;
          -  Written consent for participation in the study&#xD;
&#xD;
          -  Patient completed lactation&#xD;
&#xD;
          -  Dysglycemia (impaired fasting glucose [IFG}, impaired glucose tolerance [IGT} or&#xD;
             IFG/IGT) and/or ß-cell dysfunction postpartum requiring pharmacological intervention&#xD;
             (except type 1 or 2 diabetes)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Personal or family history of medullary thyroid carcinoma or in patients with Multiple&#xD;
        Endocrine Neoplasia syndrome type 2&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Significant cardiovascular, cerebrovascular, renal, or hepatobiliary diseases in the&#xD;
             past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology)&#xD;
&#xD;
          -  Serum liver enzymes (AST and/or ALT levels) exceeding more than twice normal&#xD;
             laboratory values&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure&gt;150 mm Hg and/or diastolic blood&#xD;
             pressure &gt;90 mm Hg)&#xD;
&#xD;
          -  Fasting serum triglycerides ≥800 mg/dl at screening. Lipid-lowering medications must&#xD;
             have been maintained at the same dose for 3 months prior to enrollment&#xD;
&#xD;
          -  Hematological profiles considered to be clinically significant&#xD;
&#xD;
          -  Cholestasis during the past pregnancy&#xD;
&#xD;
          -  Presence of contradictions for GLP-1 receptor agonist or metformin administration such&#xD;
             as allergy or hypersensitivity&#xD;
&#xD;
          -  Current use of metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors or&#xD;
             GLP-1 receptor agonist medications.&#xD;
&#xD;
          -  Use of drugs known to exacerbate glucose tolerance.&#xD;
&#xD;
          -  Use of prescription or over-the-counter weight-loss drugs&#xD;
&#xD;
          -  Diabetes postpartum or history of diabetes or prior use of medications to treat&#xD;
             diabetes except gestational diabetes&#xD;
&#xD;
          -  Creatinine clearance less than 60 ml/min&#xD;
&#xD;
          -  History or currently undergoing chemotherapy or radiotherapy for cancer&#xD;
&#xD;
          -  Pregnancy planned during the coming two years&#xD;
&#xD;
          -  Currently breastfeeding&#xD;
&#xD;
          -  Exclusion criteria include any condition, which in the opinion of the investigator&#xD;
             would place the subject at increased risk or otherwise make the subject unsuitable for&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Elkind-Hirsch, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renee Harris, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>June 10, 2019</results_first_submitted>
  <results_first_submitted_qc>July 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Scientific Director of Research</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes mellitus</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>metabolic dysfunction</keyword>
  <keyword>impaired fasting glucose</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>incretin mimetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>153 met criteria and were randomized</recruitment_details>
      <pre_assignment_details>166 were consented but 153 met criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin XR Plus Liraglutide</title>
          <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
        </group>
        <group group_id="P2">
          <title>Metformin XR Plus Placebo</title>
          <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>intolerant to side effects</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Allergic reaction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin XR Plus Liraglutide</title>
          <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
        </group>
        <group group_id="B2">
          <title>Metformin XR Plus Placebo</title>
          <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI greater than/equal to 25</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion-Sensitivity Index (IS-SI)</title>
        <description>IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET)</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion-Sensitivity Index (IS-SI)</title>
          <description>IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET)</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.4" spread="387"/>
                    <measurement group_id="O2" value="333" spread="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures design</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose (FBG)</title>
        <description>Fasting glucose levels in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose (FBG)</title>
          <description>Fasting glucose levels in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="6.4"/>
                    <measurement group_id="O2" value="91.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.005</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose During OGTT (MBG)</title>
        <description>MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose During OGTT (MBG)</title>
          <description>MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="20.8"/>
                    <measurement group_id="O2" value="118.8" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.011</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.4"/>
                    <measurement group_id="O2" value="2.45" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nested repeated measures design</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Insulin Sensitivity Index Derived From OGTT</title>
        <description>OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Insulin Sensitivity Index Derived From OGTT</title>
          <description>OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.9"/>
                    <measurement group_id="O2" value="5.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.03</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulinogenic Index (IGI) /HOMA-IR</title>
        <description>IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index (IGI) /HOMA-IR</title>
          <description>IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.14"/>
                    <measurement group_id="O2" value="0.62" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Body Weight</title>
        <description>Body weight in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Body Weight</title>
          <description>Body weight in LIRA-MET group compared with PL-MET group</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" spread="18.6"/>
                    <measurement group_id="O2" value="91.3" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.048</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)</title>
        <description>Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent.</description>
        <time_frame>Change from baseline (time 0) to study end (84 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)</title>
          <description>Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent.</description>
          <units>percent change in weight from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="1.3"/>
                    <measurement group_id="O2" value="-3.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group</description>
          <units>weight (kg) /height (m) squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="5.2"/>
                    <measurement group_id="O2" value="32.8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.047</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (WC)</title>
        <description>Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (WC)</title>
          <description>Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" spread="15.2"/>
                    <measurement group_id="O2" value="95.3" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.023</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-Hip Ratio (WHR)</title>
        <description>Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-Hip Ratio (WHR)</title>
          <description>Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group</description>
          <units>ratio of waist/hip circumference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".81" spread=".04"/>
                    <measurement group_id="O2" value=".81" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist to Height Ratio (WHtR)</title>
        <description>Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Waist to Height Ratio (WHtR)</title>
          <description>Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group</description>
          <units>ratio of waist /height</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".56" spread=".08"/>
                    <measurement group_id="O2" value=".57" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol (CHOL) Levels</title>
        <description>CHOL levels in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol (CHOL) Levels</title>
          <description>CHOL levels in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.7" spread="36"/>
                    <measurement group_id="O2" value="183.8" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol (HDL-C) Levels</title>
        <description>HDL-C levels in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL-C) Levels</title>
          <description>HDL-C levels in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="12.6"/>
                    <measurement group_id="O2" value="48.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein Cholesterol (LDL-C) Levels</title>
        <description>LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-C) Levels</title>
          <description>LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="32"/>
                    <measurement group_id="O2" value="107" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride (TRG) Levels</title>
        <description>TRG concentrations in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride (TRG) Levels</title>
          <description>TRG concentrations in LIRA-MET group compared with PL-MET group</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="64.5"/>
                    <measurement group_id="O2" value="125" spread="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.046</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)</title>
        <description>TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)</title>
          <description>TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group</description>
          <units>ratio of TRG (mg/dL)/HDL-C (mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.5"/>
                    <measurement group_id="O2" value="2.95" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.049</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>SBP in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>SBP in LIRA-MET group compared with PL-MET group</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="12"/>
                    <measurement group_id="O2" value="123" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>DBP in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>DBP in LIRA-MET group compared with PL-MET group</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="8.9"/>
                    <measurement group_id="O2" value="77" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) Levels</title>
        <description>Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) Levels</title>
          <description>Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="10.7"/>
                    <measurement group_id="O2" value="31" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <description>The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="8"/>
                    <measurement group_id="O2" value="28" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio</title>
        <description>ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group</description>
        <time_frame>84 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR Plus Liraglutide</title>
            <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
          </group>
          <group group_id="O2">
            <title>Metformin XR Plus Placebo</title>
            <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio</title>
          <description>ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group</description>
          <units>ratio of ALT (U/L)/ AST (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.4"/>
                    <measurement group_id="O2" value="1.18" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected over 5 years of trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin XR Plus Liraglutide</title>
          <description>Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated&#xD;
Metformin XR plus liraglutide: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)</description>
        </group>
        <group group_id="E2">
          <title>Metformin XR Plus Placebo</title>
          <description>Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated&#xD;
Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>expected side effect of medication</description>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>diarrhea and bloating on higher dose of medication</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to liraglutide</sub_title>
                <description>rash developed at injection site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A large percentage of patients did not complete the trial with the greatest loss from first study visit to second visit. A greater loss was seen initially in the metformin only group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>225 231-5275 ext 2</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

